BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Feb. 11, 2003
View Archived Issues
NeoPharm to resume LEP clinical trials
Read More
Antitumor protein tyrosine kinase inhibitors newly identified at Pfizer
Read More
New analgesic agents in early development at Gruenenthal
Read More
Merck researchers describe new DPP-IV inhibitors for diabetes and other disorders
Read More
Antiarrhythmic benzopyran derivatives prepared and tested at Nissan Chemical
Read More
NPS updates clinical progress
Read More
Atheroprotective effects of statins
Read More
FK-960 distribution evaluated in rhesus monkeys
Read More
Revotar and Texas Biotechnology amend bimosiamose license agreement
Read More
BioCryst refocuses resources following termination of peramivir agreement
Read More
Rigel reports accomplishments in 2002 and outlook for 2003
Read More
Pilot study for DB-289 completes enrollment
Read More
Phase II/III trial planned for iseganan for prevention of VAP
Read More
Metvix launched in Germany
Read More
FDA approves Avonex for early MS
Read More
Merck & Co. discontinues development of GABA agonist
Read More
MIV-210 enters phase I study of multiple oral doses
Read More
Fludara receives E.U. approval as first-line treatment for B-CLL
Read More
Wyeth presents various series of PAI-1 inhibitors
Read More
New ORL1 modulators in early development at Pfizer
Read More
Raptiva enters phase II trial in psoriatic arthritis
Read More
Novo Nordisk updates progress of R&D portfolio
Read More
First potent human MC1 receptor antagonist disclosed in recent article
Read More
Clinical toxicity and pharmacokinetics determined for lead alkycycline
Read More
Beneficial effects for SAR-943 on inflammation and remodeling in murine asthma model
Read More